PAH Diagnosis and Treatment: Leveraging an Unbounded Simulation World to Advance Practice Improvement
Release: 5/15/2023; Expiration: 5/15/2024
Activity Overview
In this activity, you will learn to identify patients at-risk for pulmonary arterial hypertension (PAH), apply the diagnostic criteria and classification of PAH, and individualize evidence-based treatment for patients with PAH. Virtual patient simulation technology will be used to create a virtual, yet realistic, environment where you will deliver care to multiple patients, receive feedback regarding your clinical approach, and observe the direct impact of your clinical decisions on patient outcomes. After completing this activity, you will have the knowledge and strategies needed to identify and treat PAH early to improve patient outcomes.
Target Audience
This activity is designed for an audience of nurses, nurse practitioners, physicians, and physician assistants.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Identify patients at-risk for PAH.
- Apply the diagnostic criteria and classification of PAH to effectively diagnose PAH in a timely manner.
Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have any questions relating to the accreditation of this activity, please contact AKH at wendi@akhcme.com
CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.
In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Credit being awarded: 1 ANCC contact hours
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 5/15/2024. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioner
AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 1 contact hour(s) (which includes 1 hour(s) of pharmacology).
Commercial Support
This activity is supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Disclosures
DISCLOSURES |
||
Name |
Relationship |
Commercial Interest |
Aaron Waxman, MD, PhD |
Advisor
Researcher |
United Therapeutics, Gossamer Acceleron/Merck, Pharmosa Actelion - J&J, AI Therapeutics |
Dorothy Caputo, MA, BSN, RN, Senior Director of Continuing Education & Compliance |
N/A |
Nothing to disclose |
Bernadette Makar, MSN, APRN-BC, NP-C (planner/reviewer) |
N/A |
Nothing to disclose |
Michele Bielarski, RN (planner/reviewer) |
N/A |
Nothing to disclose |
AKH Inc Staff and Planners |
N/A |
Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated. |
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content.